CytomX Therapeutics: Leaning Into The Hype, But What's Next?

Impact · against what's priced in

CTMX is positively impacted by strong Phase 1 data for CX-2051 and a comfortable cash runway extending into 2027. The breadth of disease control in refractory colorectal cancer provides a concrete valuation catalyst for the lead asset.

CTMX+0.70

No priced-in read yet

In context

The lead candidate CX-2051 showed disease control in nearly all Phase 1 refractory colorectal cancer patients, while a cash position of $143.6 million in total liquidity secures operations through Q2 2027.

Read from the article alone

• colorectal cancerNew
• clinical trials▲6%
• biotech
• CTMX
• antibody
• cancer
• oncology
• phase 1